ArticleHepatology communications2019
Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial.
Article in Hepatology communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis.Gut · 2025Guideline
- Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions.Systematic reviews · 2021Pooled it
- Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2020Pooled it
- Autoimmune liver diseases in Latin America: Current landscape and challenges.Hepatology communications · 2026Article
- Autoimmune Hepatitis and Systemic Lupus Erythematosus Overlap Syndrome: A Case Report and Literature Review.Cureus · 2024Article
- Alcohol-induced Golgiphagy is triggered by the downregulation of Golgi GTPase RAB3D.Autophagy · 2024Article
- Advancements in autoimmune hepatitis management: Perspectives for future guidelines.World journal of hepatology · 2024Article
- Article
- Validating a novel algorithm to identify patients with autoimmune hepatitis in an administrative database.Pharmacoepidemiology and drug safety · 2021Article
- Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.Pharmacology & therapeutics · 2020Review
- Particularities of Autoimmune Hepatitis in Latin America.Clinical liver disease · 2020Review
- Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial.JGH open : an open access journal of gastroenterology and hepatology · 2020Article
- Assessment of Hydroxychloroquine and Chloroquine Safety Profiles: A Systematic Review and Meta-Analysis.medRxiv : the preprint server for health sciences · 2020Article
- Inhibitory Effects of DietaryFrontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Between 50% and 86% of patients with autoimmune hepatitis (AIH) relapse after immunosuppression withdrawal; long-term immunosuppression is associated with increased risk of neoplasias and infections. Chloroquine diphosphate (CQ) is an immunomodulatory drug that reduces the risk of flares in rheumatologic diseases. Our aims were to investigate the efficacy and safety of CQ for maintenance of biochemical remission of AIH in a double-blind randomized trial and to define a subgroup that obtained a greater benefit from its use. A total of 61 patients with AIH in histologic remission (90.1% AIH type 1 [AIH-1]) were randomized to receive CQ 250 mg/day or placebo for 36 months. Of the 61 patients, 31 received CQ and 30 placebo. At baseline, clinical, laboratory, histologic findings, and human leukocyte antigen (HLA) profile were similar between the two groups. Relapse-free survival was significantly higher in the CQ group compared to the placebo group (59.3% and 19.9%, respectively
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.